Advertisement
Lipella Pharmaceuticals I... (LIPO)
Lipella Pharmaceuticals Statistics
Share Statistics
Lipella Pharmaceuticals has 2.55M shares outstanding. The number of shares has increased by -66.49% in one year.
| Shares Outstanding | 2.55M |
| Shares Change (YoY) | -66.49% |
| Shares Change (QoQ) | 110.83% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.9M |
| Failed to Deliver (FTD) Shares | 2K |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 17.27K, so 0.68% of the outstanding shares have been sold short.
| Short Interest | 17.27K |
| Short % of Shares Out | 0.68% |
| Short % of Float | 0.74% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.64 and the forward PE ratio is -0.15. Lipella Pharmaceuticals's PEG ratio is 0.03.
| PE Ratio | -0.64 |
| Forward PE | -0.15 |
| PS Ratio | 5.96 |
| Forward PS | 0.1 |
| PB Ratio | 1.67 |
| P/FCF Ratio | -0.81 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lipella Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.47, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.47 |
| Quick Ratio | 3.47 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $107.27K |
| Profits Per Employee | $-1M |
| Employee Count | 5 |
| Asset Turnover | 0.2 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -54.66% in the last 52 weeks. The beta is 0.31, so Lipella Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.31 |
| 52-Week Price Change | -54.66% |
| 50-Day Moving Average | 2.6 |
| 200-Day Moving Average | 3.18 |
| Relative Strength Index (RSI) | 56.71 |
| Average Volume (20 Days) | 2.25M |
Income Statement
In the last 12 months, Lipella Pharmaceuticals had revenue of 536.36K and earned -5.02M in profits. Earnings per share was -4.79.
| Revenue | 536.36K |
| Gross Profit | -3.08M |
| Operating Income | -5.08M |
| Net Income | -5.02M |
| EBITDA | -5.01M |
| EBIT | -5.02M |
| Earnings Per Share (EPS) | -4.79 |
Balance Sheet
The company has 2.18M in cash and 47.6K in debt, giving a net cash position of 2.14M.
| Cash & Cash Equivalents | 2.18M |
| Total Debt | 47.6K |
| Net Cash | 2.14M |
| Retained Earnings | -15.34M |
| Total Assets | 2.67M |
| Working Capital | 1.86M |
Cash Flow
In the last 12 months, operating cash flow was -3.95M and capital expenditures 0, giving a free cash flow of -3.95M.
| Operating Cash Flow | -3.95M |
| Capital Expenditures | 0 |
| Free Cash Flow | -3.95M |
| FCF Per Share | -3.77 |
Margins
Gross margin is -573.65%, with operating and profit margins of -947.23% and -935.25%.
| Gross Margin | -573.65% |
| Operating Margin | -947.23% |
| Pretax Margin | -935.25% |
| Profit Margin | -935.25% |
| EBITDA Margin | -934.71% |
| EBIT Margin | -947.23% |
| FCF Margin | -736.59% |
Dividends & Yields
LIPO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LIPO is $16, which is 508.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $16 |
| Price Target Difference | 508.4% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Nov 8, 2024. It was a backward split with a ratio of 1:8.
| Last Split Date | Nov 8, 2024 |
| Split Type | backward |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | -8.06 |
| Piotroski F-Score | 1 |